<DOC>
	<DOCNO>NCT00042939</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Monoclonal antibody cetuximab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Combining chemotherapy cetuximab may kill tumor cell . PURPOSE : This randomized phase II trial study give irinotecan docetaxel together cetuximab see well work compare irinotecan docetaxel alone treat patient metastatic pancreatic cancer .</brief_summary>
	<brief_title>Irinotecan Docetaxel With Without Cetuximab Treating Patients With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy irinotecan docetaxel without cetuximab , term objective response rate , patient metastatic adenocarcinoma pancreas . - Determine time progression overall survival patient treat regimen . - Determine proportion patient tumor overexpress epidermal growth factor receptor . OUTLINE : This randomize , multicenter study . Patients randomize 1 2 treatment arm . - Arm A : Patients receive docetaxel IV 1 hour irinotecan IV 30 minute weekly day 1 , 8 , 15 , 22 . - Arm B : Patients receive docetaxel irinotecan arm A . Patients also receive cetuximab IV 1-2 hour day 1 , 8 , 15 , 22 , 29 , 36 . Courses repeat arm every 6 week absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year , every 6 month 1 year , periodically thereafter . PROJECTED ACCRUAL : A total 92 patient ( 46 per treatment arm )</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically confirm metastatic adenocarcinoma pancreas Sufficient tumor tissue fine needle aspiration , core biopsy , open biopsy available epidermal growth factor receptor test At least 1 unidimensionally measurable primary metastatic lesionge Age 18 ECOG performance status 01 Negative pregnancy test Fertile patient must use effective contraception Creatinine clearance &gt; 60 mL/min LVEF normal Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Bilirubin ≤ upper limit normal ( ULN ) * SGOT SGPT alkaline phosphatase must meet criterion 1 following* : SGOT SGPT ≤ 2.5 time ULN AND alkaline phosphatase ≤ ULN SGOT SGPT ≤ 1.5 time ULN AND alkaline phosphatase &gt; ULN ≤ 2.5 time ULN SGOT SGPT ≤ ULN AND alkaline phosphatase &gt; 2.5 ≤ 4 time ULN NOTE : *Percutaneous stenting endoscopic retrograde cholangiopancreatography may use normalize liver function test History uncontrolled arrhythmias History congestive heart failure History uncontrolled angina pectoris Prior chemotherapy Preexisting neuropathy ≥ grade 2 Prior hypersensitivity polysorbate 80 Pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>pancreatic cancer</keyword>
	<keyword>metastatic pancreatic cancer</keyword>
	<keyword>EGF-r</keyword>
	<keyword>irinotecan</keyword>
	<keyword>docetaxel</keyword>
	<keyword>cetuximab</keyword>
</DOC>